Diabetes
Latest News
Dapagliflozin meets primary endpoint in the DAPA-HF trial
AstraZeneca announces preliminary results in first heart failure trial in an SGLT2 inhibitor.
From the Journals
Diabetes effect in heart failure varies by phenotype
In a pan-Asian cohort of heart failure patients with diabetes, there were differences in cardiac remodeling between patients with preserved left...
From the Journals
Diabetes targets remain elusive for patients
Cascade of diabetes care in the United States has not improved since 2005.
Latest News
Oral semaglutide monotherapy delivers HbA1c improvements in type 2 diabetes
Adult patients with type 2 diabetes showed significant improvements in HbA1c, compared with placebo.
Latest News
Mediterranean diet tied to improved cognition in type 2 diabetes
The association was significant in those with effective glycemic control.
Latest News
Endoscopic duodenal mucosal resection found effective for some patients with T2D
No unanticipated serious adverse events were reported and a single DMR-related serious adverse event was reported.
From the Journals
Endocrine Society advises on diabetes care for older adults
A clinical practice guideline from the Endocrine Society addresses the impact of aging on patients with diabetes aged 65 years and older.
From the Journals
No increase in UTI risk with SGLT-2 inhibitors
compared...
News
FDA approves Baqsimi nasal powder for emergency hypoglycemia treatment
It is the first glucagon therapy approved for this indication that is administrable without an injection.
From the Journals
Inadequate glycemic control in type 1 diabetes leads to increased fracture risk
Each percentage increase in hemoglobin level was associated with a 7% increase in fracture risk.
Conference Coverage
DECLARE-TIMI58 shows improved kidney function with dapagliflozin
SAN FRANCISCO – The SGLT2 dapagliflozin was better than placebo at slowing down kidney disease in patients with type 2 diabetes